ACR Appropriateness Criteria® on Metastatic Bone Disease
نویسندگان
چکیده
منابع مشابه
ACR Appropriateness Criteria® Sinonasal Disease.
Imaging of sinonasal pathology may occur for assessment of rhinosinusitis or mass lesions. Rhinosinusitis is prevalent in up to 16% of the US population with annual economic burdens estimated at 22 billion dollars. Rhinosinusitis is characterized as acute or chronic based on symptom duration; if four or more episodes occur annually, the term recurrent acute rhinosinusitis (RARS) is used. In acu...
متن کاملACR Appropriateness Criteria® Cerebrovascular Disease.
Diseases of the cerebral vasculature represent a heterogeneous group of ischemic and hemorrhagic etiologies, which often manifest clinically as an acute neurologic deficit also known as stroke or less commonly with symptoms such as headache or seizures. Stroke is the fourth leading cause of death and is a leading cause of serious long-term disability in the United States. Eighty-seven percent o...
متن کاملACR Appropriateness Criteria: rectal cancer-metastatic disease at presentation.
In 2009, an estimated 40,870 new cases of rectal cancer will be diagnosed in the USA. After decades of treating metastatic colorectal cancer (CRC) with 5-fluorouracil alone, newer agents have resulted in significant improvements in disease-free and overall survival rates. These improvements stem from combinations of newer cytotoxic agents and targeted therapies. Based on performance status and ...
متن کاملACR Appropriateness Criteria® Rectal Cancer: Metastatic Disease at Presentation
The management of rectal cancer in patients with metastatic disease at presentation is highly variable. There are no phase III trials addressing therapeutic approaches, and the optimal sequencing of chemotherapy, radiation therapy, and surgery remains unresolved. Although chemoradiation is standard for patients with stage II/III rectal cancer, its role in the metastatic setting is controversial...
متن کاملACR Appropriateness Criteria® on Cerebrovascular Disease
Stroke is the sudden onset of focal neurologic symptoms due to ischemia or hemorrhage in the brain. Current FDA-approved clinical treatment of acute ischemic stroke involves the use of the intravenous thrombolytic agent recombinant tissue plasminogen activator given Ͻ3 hours after symptom onset, following the exclusion of intrace-rebral hemorrhage by a noncontrast CT scan. Advanced MRI, CT, and...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Radiology
سال: 2010
ISSN: 1546-1440
DOI: 10.1016/j.jacr.2010.02.015